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Neurobiology of Disease
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Alzheimer’s disease (AD) is themost commonprogressive neurodegenerative disorder causing dementia.Massive deposition of amyloid
peptide (A) as senile plaques in the brain is the pathological hallmarkofAD, but oligomeric, soluble formsofAhavebeen implicated
as the synaptotoxic component. The apolipoprotein E 4 (apoE4) allele is known to be a genetic risk factor for developingAD.However,
it is still unknown how apoE impacts the process of A oligomerization. Here, we found that the level of A oligomers inAPOE 4/4 AD
patient brains is 2.7 times higher than those in APOE 3/3 AD patient brains, matched for total plaque burden, suggesting that apoE4
impacts themetabolism of A oligomers. To test this hypothesis, we examined the effect of apoE on A oligomer formation. Using both
synthetic A and a split-luciferasemethod formonitoringA oligomers, we observed that apoE increased the level of A oligomers in an
isoform-dependentmanner (E2E3E4). This effect appears tobedependent on theApoEC-terminal domain.Moreover, these results
were confirmed using endogenous apoE isolated from the TBS-soluble fraction of human brain, which increased the formation of A
oligomers. Together, these data show that lipidated apoE, especially apoE4, increases A oligomers in the brain. Higher levels of A
oligomers in the brains of APOE 4/4 carriers compared with APOE 3/3 carriers may increase the loss of dendritic spines and
accelerate memory impairments, leading to earlier cognitive decline in AD.
Introduction
The hallmark of Alzheimer’s disease (AD) is deposition of fibril-
lar amyloid  peptide (A) in senile plaques in the brain (Selkoe,
2001; Holtzman et al., 2011). Recent data, however, suggest that
instead of, or in addition to, plaques, soluble oligomeric forms of
A are crucial for synaptic dysfunction, cognitive impairment
and neurodegeneration (Lesne´ et al., 2006; Shankar et al., 2008;
Koffie et al., 2009; Wu et al., 2010). However, it is still unknown
what factors influence the kinetics of formation of soluble A
oligomers.
Apolipoprotein E (apoE) is a known A binding protein and
is a genetic risk factor for AD (Bu, 2009). There are 3 common
alleles of the human APOE gene 2, 3, and 4 (Zannis et al.,
1982). Inheritance of two copies of the APOE 4 allele is associ-
ated with a10-fold increased risk for developing AD compared
with the most common APOE 3/3 genotype (Corder et al.,
1993; Strittmatter et al., 1993a). However, the mechanisms
wherebyAPOE 4 promotes the development of AD remain con-
troversial. There is strong evidence that apoE, and particularly
apoE4, facilitates amyloid fibril deposition. Senile plaque density
in the brains of APOE 4/4 carrier AD patients is significantly
higher than that in the brains of APOE 3/3 carrier AD patients
(Rebeck et al., 1993; Gomez-Isla et al., 1996). apoE-deficientmice
crossed with APP (amyloid precursor protein)-transgenic mice
exhibited a decrease in amyloid deposition in the brain, and hu-
man apoE4 overexpression increased fibrillar A deposits com-
pared with human apoE3 (Holtzman et al., 2000; Fagan et al.,
2002). Moreover, recent studies support a role of apoE in A
metabolism. Using an in vivo microdialysis technique, the half-
life of A in the brain of apoE knock-out mice markedly de-
creased compared with wild-type mice (DeMattos et al., 2004).
Importantly, it has now been shown that in APP-transgenic mice
expressing apoE2, E3, and E4, apoE4 significantly slows A clear-
ance relative to E2 and E3 but has no effect on A synthesis
(Castellano et al., 2011).
Previous studies have revealed that apoE interacts with A in
vitro (Strittmatter et al., 1993b; LaDu et al., 1994) and in vivo,
both in the CSF (Strittmatter et al., 1993a) and in the brain (Na¨s-
lund et al., 1995). However, because of the difficulty in monitor-
ing A oligomers specifically and quantitatively, whether apoE
increases the levels of native A oligomers remains unknown. In
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this study we hypothesize that apoE, especially apoE4, impacts
the formation of A oligomers. We observed significantly in-
creased levels of A oligomers in APOE 4/4 AD patient brains
compared with APOE 2/x or APOE 3/3 AD patient brains.
We also found that apoE4 enhances the level of A oligomers,
using a split-luciferase complementation assay that enables
quantitative monitoring of the formation of A oligomers. Fur-
thermore, endogenous apoE from human brain also increased
the level of A oligomers in vitro. These data suggest that apoE,
especially apoE4, impacts A oligomer levels by enhancing their
formation and stabilizing them once formed.
Materials andMethods
Brain extraction and gel filtration. Brains from human subjects with a
diagnosis of Alzheimer’s disease or no cognitive deficits were obtained
through the Massachusetts Alzheimer’s Disease Research Center. Cases
were selected to have equivalent amyloid load (Ingelsson et al., 2004) and
to be either APOE 2/x, APOE 3/3, or APOE 4/4; these data were
not revealed during subsequent biochemical assays. The case number is 8
in control (4males and 4 females), 6 inAPOE 2/xAD (6 females), 10 in
APOE 3/3 AD (4 males and 6 females) or 10 in APOE 4/4 AD (5
males and 5 females). Cortical gray matter from frontal lobe of AD pa-
tient brains or non-demented control brains was homogenized in 5 vol-
umes of TBSI (Tris-buffered saline with Protease Inhibitor Cocktail;
Roche) with 25 strokes on a mechanical Dounce homogenizer and cen-
trifuged at 260,000 g for 30 min at 4°C. The supernatant was used as a
TBS-soluble fraction (Hashimoto et al., 2002). TBS-soluble fraction (750
l) of human brains was separated by size-exclusion chromatography
(SEC) on single or double Superdex 75 columns (GE Healthcare) in 50
mM ammonium acetate, pH 8.5, with an AKTA purifier 10 (GE Health-
care; Townsend et al., 2006). Conditioned medium from HEK293 cells
(750 l) was separated by size exclusion chromatography on a Superdex
200 column (GEHealthcare) in 50 mM ammonium acetate, pH 8.5, with
anAKTApurifier 10 (GEHealthcare). The individual fractions separated
by SEC were analyzed by immunoblotting and A-specific sandwich
ELISA.
cDNA plasmids. Human ApoE2, ApoE3, and ApoE4 genes were a gift
from Dr. Mary Jo LaDu at University of Illinois at Chicago. The human
ApoA-I gene was purchased from the full-length mammalian gene col-
lection (Invitrogen) and subcloned into pcDNA3.1 vector (Invitrogen)
between HindIII site and BamHI site using the following primers: 5-GA
GAAGAAGCTTCCCCACGGCCCTTCAGG-3 (forward), 5-ATTC
TGGGATCCGGGAAGGGGGGCGGCGG-3 (reverse). The human
ApoA-II gene was also purchased from the full-length mammalian gene
collection and subcloned into pcDNA3.1 vector betweenHindIII site and
BamHI site using the following primers: 5-ACAGAGAAGCTTGCTA
GGCCGCCCTCCCC-3(forward),5-GGGACAGGATCCCTAGGACT
GGCCAGTGGG-3 (reverse). The human ApoJ/clusterin gene was
purchased from the full-length mammalian gene collection and sub-
cloned into pcDNA3.1 vector betweenHindIII site and BamHI site using
the following primers: 5-TGACCGAAGCTTGCAAAGACTCCAGAAT
TGG-3 (forward), 5-AGTGCAGGATCCAGAGCGGGGAGAGG-3
(reverse). For the apoE4 R61T mutant, we mutated Arg61 of apoE4
cDNA plasmid into Thr by in vitro site-directed mutagenesis using the
following primers: 5-CACCCAGGAGCTCACGGCGCTGATGG-3
(forward), 5-CCATCAGCGCCGTGAGCTCCTGGGTG-3 (reverse).
For the N-terminal fragments of apoE (apoE2 NTF, apoE3 NTF, and
apoE4 NTF), we deleted apoE192–299 from the apoE2, apoE3, and
apoE4 cDNA plasmids, respectively, using the following primers: 5-TG
AACGCCGAAGCCTGCAGCCATGCG-3 (apoE1–191 forward), 5-CC
GCACGCGGCCCTGTTCCACCAGGGG-3 (apoE1–191 reverse). For
the C-terminal fragment of apoE (apoE CTF), we deleted apoE1–191
from the apoE2 cDNA plasmid using the following primers: 5-GCCG
CCACTGTGGGCTCCCTGGCC-3 (apoE192–299 forward), 5-CTTG
GCCTGGCATCCTGCCAGGAATGTG-3 (apoE192–299 reverse). The
apoE signal sequence was retained before the apoE CTF. For the
apoE231–299, we deleted apoE192–230 from the apoE CTF cDNA plas-
mid using the following primers: 5-GAGGTGAAGGAGCAGGTGGC
GGAGG-3 (apoE231–299 forward) and apoE192–299 reverse primer.
For apoE243–299, we deleted apoE192–242 from the apoE CTF cDNA
plasmid using the following primers: 5-CTGGAGGAGCAGGCCCAG
CAGATACGCC-3 (apoE243–299 forward) and apoE192–299 reverse
primer. For apoE192–272, we deleted apoE273–299 from the apoE CTF
cDNA plasmid using the following primers: apoE1–191 forward primer
and 5-CATGTCTTCCACCAGGGGCTCGAACC-3 (apoE192–272 re-
verse). For apoE192–242, we deleted apoE243–299 from the apoE CTF
cDNA plasmid using the following primers: apoE1–191 forward primer
and 5-CTTGGCGCGCACCTCCGCCACCTGC-3 (apoE192–242 re-
verse). For apoE3 243–272, we deleted apoE243–272 from the apoE3
cDNA plasmid using the following primers: 5-CAGCGCCAGTGGGC
CGGGCTGGTGG-3 (apoE273–299 forward) and apoE192–242 reverse
primer. For apoE3273–299, we deleted apoE273–299 from the apoE3
cDNA plasmid using the following primers: apoE1–191 forward primer
and apoE192–272 reverse primer. For apoE3243–299, we deleted
apoE243–299 from the apoE3 cDNA plasmid using the following prim-
ers: apoE1–191 forward primer and apoE192–242 reverse primer.
Cell culture and transient transfection.BothN-terminal andC-terminal
fragments of split-luciferase-tagged A stably overexpressing HEK293
cells (doubly expressing HEK293 cells) were generated previously
(Hashimoto et al., 2011). Doubly expressing HEK293 cells were cultured
in Opti-MEM (Invitrogen) with 10% fetal bovine serum at 37°C in 5%
CO2 atmosphere. Transient apoEs or apoE mutants expressing cell lines
were generated by transfecting cDNA plasmids using Lipofectamine
2000 (Invitrogen) as suggested by themanufacturer. For luciferase assays
of the conditionedmedium, we incubated HEK293 cells 24 h after trans-
fection, changed the medium to Opti-MEM without fetal bovine serum
for 24 h at 37°C in 5% CO2 atmosphere, and collected conditioned me-
dium. For luciferase assays of the cell lysate, we washed the cells with PBS
and harvested them with Lysis Buffer (Promega).
Immunoblotting, sandwich ELISA, immunodepletion, immunoprecipi-
tation. Brain TBS-soluble fractions, individual SEC fractions or condi-
tioned media from HEK293 cells were electrophoresed on 10–20% or
4–20% Novex Tris-Glycine gels (Invitrogen) in Tris-Glycine SDS run-
ning buffer for SDS-PAGE (Invitrogen). Gels were transferred to a poly-
vinylidene difluoride membrane (PolyScreen, PerkinElmer), and
blocked for 30 min at room temperature (RT) in 5% nonfat skim milk/
TBST (Tris-buffer saline with 0.1% Tween 20). Membranes were probed
with 1 g/ml monoclonal anti-A antibody 6E10 (Signet) or 82E1 (IBL
International), anti-apoE antibody 6C5 (OttawaHeart Institute), or 3H1
(Ottawa Heart Institute) in TBST for 2 h at RT or for 12 h at 4°C.
Following incubation with horseradish peroxidase-conjugated second-
ary antibody (Bio-Rad) for 1 h at RT, immunoreactive proteins were
developed using an ECL kit (Western Lightning, PerkinElmer) and de-
tected on Hyperfilm ECL (GE Healthcare; Jones et al., 2011). For the
A40 and A42 quantification, individual SEC fractions were diluted
and subjected to BNT77/BA27 for A40, or BNT77/BC05 for A42 using
two-site ELISAs (WAKO Chemicals) and quantified as suggested by the
manufacturer. For guanidine treatment, individual SEC fractions were
incubated with 8 M guanidine-HCl (concentration of guanidine-HCl in
the sample is 4 M) for 30 min at room temperature, diluted by 7 volumes
of standard dilution buffer (final concentration of guanidine-HCl in the
sample is 0.5 M) and subjected to ELISA (Yamada et al., 2009). For im-
munodepletion, we first incubated 200 l of SEC-separated fractions
with 30 l of protein G magnetic beads (Millipore) for 1 h at 4°C and
removed beads by using a magnet. We next incubated supernatants with
or without 5g of anti-human apoEmAb 3H1 or anti-ApoA-ImAb 4H1
(Ottawa Heart Institute) for 12 h at 4°C. We further incubated samples
with 30 l of protein Gmagnetic beads for 2 h at 4°C, removed beads by
using a magnet, and collected the supernatant as immunodepleted sam-
ples. For immunoprecipitation, we first incubated 200 l of SEC-
separated fractions with 30l of protein-G Sepharose beads (Invitrogen)
for 1 h at 4°C and removed beads by centrifugation at 8000 rpm for 5min
at 4°C. The supernatants were incubated with anti-apoE (Millipore, Cal-
biochem), anti-A (6E10), or control Ig (anti-p-glycoprotein) for 8 h at
4°C. Incubated samples were centrifuged at 8000 rpm for 5 min at 4°C
and the pellets were washed by TBST 2 times, incubated with sample
buffer for 10 min at 95°C, and applied to SDS-polyacrylamide gels.
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Statistical analysis was performed by one-way ANOVA using Prism 5
for Mac OSX (GraphPad). Following ANOVA, Bonferroni’s or Tukey’s
post hoc test was applied.
A Immunohistochemistry and amyloid burden analysis. Eight-micrometer-
thick paraffin-embedded sections from the frontal association cortex (Brod-
mann’s area 8,9) were obtained from the Massachusetts General Hospital
Alzheimer Disease Research Center Brain Bank. Sections were deparaf-
finized with xylenes, rinsed in H2O2 0.3% in methanol for 20 min to block
the endogenous peroxidase activity, and hydrated with decreasing concen-
trations of ethanol. Antigen retrieval before immunostaining was achieved
by microwaving the sections in citrate buffer (0.01 M citric acid anhydrous,
Tris-buffered saline, 0.05%Tween 20, NaOH to pH6.0) at 95°C for 20min,
followed by a rinse in formic acid 90% for 5 min. After extensive washing,
sections were blocked with 5% nonfat milk for 1 h to avoid nonspecific
binding of the primary antibody. Sections were incubated overnight at
4°C with the N-terminal-specific anti-A 10D5 mouse monoclonal
antibody (1:50, Elan Pharmaceuticals). On the next day, sections were
thoroughly washed, incubatedwith a goat anti-mouse-HRP-linked second-
ary antibody (1:200, Jackson ImmunoResearch) for 2 h at room tempera-
ture, and developed with 3–3-diaminobenzidine. Finally, sections were
lightly counterstained with Mayer’s hematoxylin, dehydrated with increas-
ing concentrations of ethanol, cleared with xylenes, and coverslipped with
Permount mountingmedium (Fisher Scientific).
The amyloid plaque burden (or amyloid load) was measured as the
percentage of total cortical surface occupied by amyloid plaques. Plaque
burden analysis was performed using the BIOQUANT system. Briefly,
sections were placed on the motorized stage of an upright Leica DMRB
microscope that was equipped with a CCD camera (model DC330,
DAGE-MT) and coupled with BIOQUANT Nova Prime software (ver-
sion 6.90.10.MBSR). An1-cm-long strip of full-depth cortex was out-
lined under the 1.6 objective and amyloid plaques were thresholded
under the 10 objective using the appropriate tool of the software (In-
gelsson et al., 2004).
Purification of apoE from immortalized astrocytes. Lipidated apoE
particles were purified from culture media of human apoE2-, apoE3-,
or apoE4-overexpressing immortalized astrocytes using an affinity
column as described previously (Morikawa et al., 2005). Briefly, as-
trocytes were cultured in advanced DMEM (Invitrogen) with 10%
FBS. After 90–95% confluency, cells were washed by PBS and further
incubated in advanced DMEM with N-2 Supplement (Invitrogen)
and 3 mM 25-hydroxycholesterol (Sigma) during 23 d. Collected
culture media were applied onto mouse monoclonal antibody against
a human apoE (WU E-4) column. Lipidated apoE particles were
eluted from the column with 3 M sodium thiocyanate, concentrated
using Apollo centrifugal quantitative concentrators (QMWL: 150
kDa, Orbital Biosciences), and dialyzed against PBS.
In vitro A oligomerization assay. We incubated 0.1 mg/ml synthetic
A1–42 (Peptides International) with or without 10 g of purified
apoE2, apoE3, or apoE4 particles at 4°C for 0, 1.5, 6, 12, and 24 h and
immediately applied the solution to SDS-PAGE (Hori et al., 2007).
Split-luciferase complementation assay.HEK293 cells were stably trans-
fected with two plasmids, each containing a complementary split-
luciferase assay for A oligomerization, as we have recently described
(Hashimoto et al., 2011). Conditioned media from these cells were col-
lected and centrifuged at 1200 rpm for 5 min to remove cell debris. After
adding 17 g/ml coelenterazine (NanoLight Technology) diluted by
Opti-MEM into samples, luciferase activity was immediately measured
using a Wallac 1420 (PerkinElmer) plate reader.
Statistical analysis was performed by one-way ANOVA using Prism 5
forMac OSX (GraphPad). Following ANOVA, Bonferroni’s post hoc test
is applied.
Results
APOE 4/4 AD patients have higher levels of A oligomers
in their brain than do APOE 3/3 or APOE 2/x AD
patients
To investigate the effect of the different apoE isoforms on the
metabolism of A oligomers, we extracted the TBS-soluble frac-
tion from the frontal associative neocortices of 8 non-demented
controls, 6 AD patients with the APOE 2/x genotype, 10 AD
patients with the APOE 3/3 genotype, and 10 AD patients with
the APOE 4/4 genotype (Table 1). Because it is known that the
level of senile plaque density in APOE 4/4 carrier AD is on
average significantly higher than that in APOE 3/3 carrier AD
(Rebeck et al., 1993), we carefully selected brains to have equal
amyloid load in an adjacent cortical region by an immunohisto-
chemical analysis using anti-A antibody 10D5 (3.7  1.4% in
APOE 2/x ADpatients, 3.0 1.3% inAPOE 3/3 ADpatients
and 3.4  2.1% in APOE 4/4 AD patients, no significant dif-
ference; Fig. 1C). Selected brains also had a similar age at death,
gender ratio, disease duration, and postmortem interval (Table
1). An equal amount of the TBS-soluble proteins from each of
these brains was applied to SDS-polyacrylamide gels and visual-
ized by anti-human A-specific antibody 82E1 (Fig. 1A). While
no bands were detectable in the TBS-soluble fraction from con-
trol brains, a 4 kDa band, corresponding (under these denaturing
conditions) to monomeric A, was observed in the TBS-soluble
fraction from both APOE 3/3 AD patient brains and APOE
4/4 AD patient brains. We also detected an 8 kDa band corre-
sponding to SDS-stable A dimers, in the TBS-soluble fraction
from several APOE 4/4 AD patient brains. To quantitate the
concentration of A, we applied synthetic A1–42 with known
concentrations to the same gels and determined the concentra-
tion of A in each TBS-soluble fraction. Despite the AD groups
being matched for amyloid plaque burden (Fig. 1C), the level of
TBS-soluble A in APOE 4/4 AD patient brains was 2.7 times
higher than that in APOE 3/3 AD patient brains, 6.9 times
higher than that in APOE 2/x AD patient brains, and substan-
tially times higher than the barely control brains’ detectable levels
(2.7  5.0 g/g brain lysate in control, 57.8  54.6 g/g brain
lysate in APOE 2/X, 144.7  185.8 g/g brain lysate in APOE
3/3 AD patient, and 396.9 315.0 g/g brain lysate in APOE
4/4 AD patients; p  0.05, 4/4 vs 3/3; p  0.01, 4/4 vs
2/x, control, 3/3 vs control; Fig. 1B). We compared the
amount of total soluble A with the histochemically defined
amounts of amyloid deposited in senile plaques, and found no
correlation between plaque burden and levels of soluble A (Fig.
Table 1. Information about the cases used in this study
Number Age at death (years) Gender, n (% female) Disease duration (years) Postmortem interval (hours)
Controla 8 77.7 10.5 4 (50.0) NA 24.3 22.1
AD (2/x)b 6 78.8 8.7 6 (100.0) 11.7 5.2 20.0 7.1
AD (3/3) 10 78.7 10.5 6 (60.0) 11.7 4.7 14.7 8.0
AD (4/4) 10 78.5 8.0 5 (50.0) 13.6 4.6 19.6 19.0
p valuec NA 0.9977 0.8994 0.9830 0.6968
aOf these individuals, n	 2 (2/3), n	 5 (3/3), n	 1 (3/4).
bOf these individuals, n	 1 (2/2), n	 2 (2/3), n	 3 (2/4).
cOne-way Kruskal–Wallis ANOVA, except for gender, which was analyzed using2 test. Postmortem interval was not available for 2 controls and 1 AD (2/x) subject.
NA, Not applicable.
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1D, r 	 
0.01, p 	 0.95). This suggests that the amount of
TBS-soluble A is independent of the amount of deposited am-
yloid plaques.
It has also been reported that the level of apoE protein in the
brains ofAPOE 4/4 carriers is smaller than that ofAPOE 3/3
AD carriers or of APOE 2/2 carriers (Riddell et al., 2008). We
measured the concentration of apoE in TBS-soluble fraction
from the brains of control and AD cases by specific ELISA and
found that it is similar among control and AD cases regardless of
genotypes (Fig. 1E).
Figure1. The level of Aoligomers in thebrain ofAPOE4/4ADpatientswas significantly higher comparedwithAPOE3/3ADpatients.A, Immunoblottingof 50gof TBS-soluble fractions
from4 control, 5APOE3/3 AD, and 5APOE4/4 AD prefrontal brains. An anti-AmAb82E1 revealed Amonomers (arrow) and dimers (arrowhead).B, Quantification of TBS-soluble A from
8control (white squares), 6APOE2/xAD (dark squares), 10APOE3/3AD (dark triangles), and10APOE4/4ADbrains (black circles). The level ofA inAPOE4/4ADbrainswas significantly
higher comparedwith control brains,APOE2/xADbrains, andAPOE3/3ADbrains. *p0.05, **p0.01, one-wayANOVA test (Tukey’spost hoc test).C, Amyloidburden (%) in theprefrontal
cortex of 8 control (white squares), 6 APOE2/x AD (dark squares), 10 APOE3/3 AD (dark triangles), and 10 APOE 4/4 AD brains (black circles) analyzed in this study. There is no significant
difference among APOE2/x AD, between APOE3/3 AD and APOE4/4 AD brains, one-way ANOVA test (Kruskal–Wallis test). D, Correlation analysis between the level TBS-soluble A and
the level of A amyloid burden in 6 APOE 2/x AD (dark squares), 10 APOE 3/3 AD (dark triangles), and 10 APOE 4/4 AD brains (black circles). There is no significant difference. E,
Quantificationof apoE concentration in theTBS-soluble fractionof 8 control (white squares), 6APOE2/xAD (dark squares), 10APOE3/3AD (dark triangles), and10APOE4/4ADbrains (black
circles). F, Immunoblotting of SEC-separated fractions from APOE4/4 AD brain. Anti-AmAb 82E1 and 6E10 revealed A (arrow) and sAPP (arrowhead). A eluted from 94 kDa to 217 kDa as
HMWAandeluted from8.6 to16kDaas LMWA. Estimatedmolecularweight (kDa)was indicatedabove (arrowheads).G, Representativedataof the separationof 200mgof TBS-soluble fractions
of APOE 3/3 AD (triangles) and APOE 4/4 AD (squares) brains by double Superdex 75 SEC columns. The concentration of A40 is measured by A specific ELISA (BNT77-BA27) (Wako).
Estimated molecular weight (kDa) was indicated above (arrowheads). A in TBS-soluble fraction formed dimer, trimer and HMW oligomers.
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The finding of SDS-stable A dimers in the TBS-soluble frac-
tion of someAPOE 4/4 AD patients brains (Fig. 1A) prompted
us to further characterize the presence of TBS-soluble A oli-
gomers under native conditions. We separated TBS-soluble frac-
tions by SEC.We applied theTBS-soluble fraction ofAPOE 4/4
AD patient brain onto two (tandem) Superdex 75 SEC columns
(Townsend et al., 2006), collected fractions, applied the fractions
into SDS-polyacrylamide gels, and detected A by the anti-
human A antibody 6E10 (Fig. 1F). We found that fractions
eluting from 94 kDa to 217 kDa strongly exhibited 4 kDa A
[hereafter called high-molecular weight (HMW) A] and frac-
tions eluting from 8.6 kDa to 16 kDa also exhibited 4 kDa A
[hereafter called low-molecular weight (LMW) A]. To confirm
these results and further refine this char-
acterization, we applied the TBS-soluble
fractions from 3 APOE 3/3 and 6 APOE
4/4 AD patients’ brains onto two (tan-
dem) Superdex 75 SEC columns, collected
the eluted fractions, and measured the
concentration of A by an A-specific
ELISA (Fig. 1G). Similar to the result of
immunoblotting above (Fig. 1E), we
found that A eluted into fractions from
100 to 200 kDa as HMW A, fractions
around 90 kDa, fractions around 30 kDa,
and fractions from 6 to 20 kDa (the latter
LMWA, likely reflecting A dimers and
A trimers). Remarkably, we found that
the TBS-soluble fraction from APOE
4/4 AD patient brains exhibited sub-
stantially higher amounts of A in every
peak compared with APOE 3/3 AD pa-
tient brains. Together, the level of TBS-
soluble A oligomers in APOE 4/4 AD
patient brains was significantly higher
than that in APOE 3/3 AD patient
brains.
ApoE forms HMW complex with A
oligomers in the brains of AD patients
Compared with immunoblotting results
(Fig. 1F), we did not detect a strong signal
of A in HMW A fractions by ELISA
(Fig. 1G). We postulated that the struc-
ture of highly oligomeric A may inhibit
the interaction between A and anti-A
antibodies, or unidentified interacting
molecules with A in the HMW fraction
may interfere with the detection of A by
anti-A antibodies used in the ELISA. To
examine these possibilities, we incubated
individual SEC fractionswith orwithout 8
M guanidine-HCl for 30 min and quanti-
fied A concentration by ELISA. We
found that themeasured concentration of
A in HMW fractions dramatically in-
creased, while the levels of A in LMW
fractions exhibited no difference (Fig.
2A), consistent with the idea that epitopes
were masked in the HMW fraction.
ApoE is secreted in high-density lipo-
protein (HDL) particles in the brain. To
know whether apoE interacts with TBS-
soluble A oligomers and contributes to their apparent HMW,
we immunoprobed A and apoE protein in each SEC-separated
fraction of TBS-soluble fraction from APOE 4/4 AD patient
brain using anti-A and anti-apoE antibodies on SDS-
polyacrylamide gels (Fig. 2B).We found that A and apoE eluted
in identical fractions, ranging from 185 to 256 kDa, suggesting
that HMWAmay interact with apoE on the HDL particles. We
also detectedHMWA and apoE in similar fractions from 185 to
256 kDa using SEC-separated samples from theTBS-soluble frac-
tion of an APOE 3/3 AD patient brain. Immunoprecipitation
of apoE using each of two separate polyclonal antibodies (anti-
apoE Ig, Calbiochem; and anti-apoE Ig, Millipore) pulled down
A from these fractions (Fig. 2C). These data suggest that apoE
Figure2. apoE formsHMWcomplexwithAoligomers in thebrains of ADpatients.A, Representativedata fromguanidine-HCl
treatment for SEC-separated fractions. SEC-separated fractions from 5 to 11, from 29 to 34were incubatedwith (black) or without
(white) 8 M guanidine HCl and quantified the A concentration by specific ELISA (BNT77-BA27). B, Immunoblotting of SEC-
separated fractions (fraction 3–12) fromanAPOE4/4ADbrain. Top, Anti-mAbs 82E1 and6E10 revealedAmonomers (arrow),
dimers, and sAPP (arrowhead). Bottom, Anti-mAb 3H1 revealed apoE (arrow). Estimated molecular weight (kDa) is indicated
above (arrowheads). C, Immunoprecipitation using anti-apoE antibodies and control antibody from SEC-separated fraction 8 and
immunoblotted by an anti-AmAb 82E1. Amonomers and dimmers were detected (arrows).
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interacts with A oligomers in humanAD
brain and thus may impact their oli-
gomerization in the brain.
Purified apoE on HDL particles
enhances synthetic A1–42 oligomer
formation in vitro
We hypothesized that apoE on HDL parti-
cles would affect the A oligomerization in
the brain in an isoform-dependentmanner.
In an in vitroA fibrillization assay, apoE is
known to inhibit A fibrillization especially
in the seedingphase ofA fibrillization (Ev-
ans et al., 1995; Naiki et al., 1997). Because
these experiments used recombinant non-
lipidated apoE and because they evaluated
the level of A fibrillization using the thio-
flavinTdye,whichspecifically interactswith
-sheeted structures but not oligomers, we
reevaluated this interaction using physio-
logically relevant lipids and synthetic A.
We purified apoE lipid particles from im-
mortalized astrocyte cell lines derived from
human apoE2, apoE3, or apoE4 knock-in
mice. These immortalized astrocyte cells
are known to secrete human apoEs in
HDL-like particles into conditioned me-
dia (Morikawa et al., 2005).We incubated
0.1mg/ml (22M) syntheticA1–42with
or without 10g of purified lipidated apoE2,
apoE3,orapoE4at4°Cfor0,1.5, 6, 12,or24h
in vitro and applied the samples to SDS-
polyacrylamide gels (Fig. 3A). In the absence
of apoE, theA trimers andA tetramersdis-
appeared within 6 h and were replaced by
smear bands after 6 h (Fig. 3A, PBS panel). In
contrast, in the presence of lipidated apoE2,
apoE3,orapoE4,thebandsforA trimersand
A tetramers gradually accumulated during
the incubationperiod (Fig. 3A, apoE2, apoE3,
apoE4 panels). Of note, qualitative inspection
of the gels show that incubation of A with
apoE3 or apoE4 yielded higher levels of A
trimers and A tetramers than incubation
with apoE2. This result may suggest that lipi-
dated apoE enhanced the oligomerization of
Aor stabilized theAoligomers.Toelucidatewhether lipidated apoE
stabilizeAoligomers,we incubated syntheticA1–42oligomerswith
5g/ml lipidated apoE2, apoE3, or apoE4 for 12 h in vitro, applied the
samples toSDS-polyacrylamidegels, andquantified the levelof remain-
ingA oligomers (Fig. 3B). Lipidated apoE4 significantly increased the
level ofA trimers and tetramers comparedwith the sample incubated
without apoE(130.019.0%in trimers and235.385.4%in tetram-
ers), suggestingthatapoE4maystabilize theAoligomers.Ontheother
hand, lipidated apoE2 and apoE3did not exhibit significant increase of
the level of theAoligomers (Fig. 3B).
Because the concentration of A oligomers is quite small, it is diffi-
cult to quantitativelymonitorAoligomers using these techniques. To
evaluate the role of apoE in the formation of A oligomers, we took
advantage of a recently developed method using a split-luciferase
complementation assay (Hashimoto et al., 2011). In this assay, the
N- and C-terminal fragments of Gaussia luciferase are fused sepa-
rately toA, so that single split-luciferase-taggedAdoesnot exhibit
luminescence.Once split-luciferase-taggedA forms oligomers, the
N- and C-terminal fragments of luciferase reconstitute into a func-
tionalmolecule that exhibits luminescence (Hashimoto et al., 2011).
This technique has the advantage of monitoring A oligomers spe-
cifically and quantitatively without background from monomers.
We incubated split-luciferase-tagged A oligomers with 0, 0.1, 0.3,
0.6, 1.25, 2.5, 5, and 10 g of purified lipidated apoE2, apoE3, or
apoE4 for 24 h andmeasured the luminescence (Fig. 3C).We found
that purified lipidated apoE in a dose-dependent manner enhanced
the level of A oligomers in an isoform-dependent manner
(apoE2 apoE3 apoE4). Moreover, we isolated LMWA from
TBS-soluble fraction of the brains of APOE 4/4 AD patients by
SEC, incubated with or without 5 g of purified lipidated apoE3,
applied to two(tandem)Superdex75SECcolumnsagain, andquan-
tified the level of A by the specific ELISA. We found that after
incubationwithpurified lipidatedapoE,6.5%ofLMWA instead
elutes in the HMW A fraction (Fig. 3D, 6.5  0.3% with apoE,
Figure 3. Purified apoE-containing HDL particles enhanced oligomer formation of synthetic A1–42 in vitro. A, Immunoblot-
ting for A after incubationof 0.1mg/ml synthetic A1–42withPBS, 10gof purified apoE2, 10gof apoE3, or 10gof apoE4
for the indicated times (hours). Anti-AmAb6E10 revealedAmonomer, dimer, trimer, and tetramer (arrows).B, Band intensity
of remaining A in SDS-polyacrylamide gels after incubation of synthetic A1–42 oligomers with PBS (no), 5g/ml purified
lipidated apoE2, apoE3, or apoE4 for 12 h using an anti-A mAb 6E10. Lipidated apoE4 significantly increased the level of A
trimer and tetramer compared with no lipidated apoE samples. N	 6, average SD, *p 0.05, one-way ANOVA test (Bonfer-
roni’s test). C, Luminescence from conditionedmedia containing split-luciferase-tagged A oligomers incubated with 0, 0.1, 0.3,
0.6, 1.25, 2.5, 5, or 10g of purified apoE2 (lipid apoE2, squares), purified apoE3 (lipid apoE3, triangles), or purified apoE4 (lipid
apoE4, circles) for 24 h. N	 6, average SD, *p 0.05, one-way ANOVA test (Bonferroni’s test). D, Incubation of LMW A
isolated from TBS-soluble fractions of the AD brains with (apoE) or without (PBS) 5g of purified lipid apoE3 and separated the
samples bydouble Superdex 75 SEC columns. The concentrationof A40wasmeasuredbyA-specific ELISA (BNT77-BA27,WAKO
Chemicals) and obtained the ratio of HMW Ameasured (in fraction 7 and 8). N	 4, average SD, *p 0.05, student’ t test.
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0.5 0.7 without apoE), an increase of over tenfold. These qualita-
tive and quantitative data suggest that lipidated apoE enhances A
oligomerization and inhibited further aggregation in vitro.
apoE enhances the level of A oligomers in an isoform-
dependent manner (apoE2< apoE3< apoE4)
Using the split-luciferase complementation assay for monitor-
ing A oligomers, we further examined apoE’s effect on A
oligomers. First we transiently transfected apoA-II, apoE2,
apoE3, and apoE4 into doubly expressing HEK293 cells stably
expressing both N- and C-terminal fragments of luciferase-
tagged A, collected their conditioned media after 24 h of
incubation, and measured A oligomers by measuring lumi-
nescence in the media (Fig. 4A,B). We found that apoE2,
apoE3, or apoE4 each increased the luminescence. On the
other hand, apoA-II, one of the other apolipoproteins in brain
HDL particles, did not change the luminescence compared
with GFP transfection (91.8  5.1% in apoA-II, 200.3 
10.2% in apoE2, 275.5  15.0% in apoE3, 338.1  18.5% in
apoE4; p  0.05, E2 vs E3; E3 vs E4). apoA-II was therefore
used as a control transfection for subsequent experiments.
apoE4 significantly increased the luminescence to a greater
extent than apoE2 and apoE3, and apoE3 significantly in-
creased the luminescence to a greater extent than apoE2, sug-
gesting that apoE enhanced the level of A oligomers in an
isoform-dependent manner (apoE2  apoE3  apoE4). We
did not see any difference in the levels of apoE in the condi-
tioned media (Fig. 4B).
Although HEK293 cells transfected with human apoE3 and
apoE4 naturally secrete apoE lipoparticles into the culture media
(LaDu et al., 2006), we asked whether the induction of A oli-
gomerization by apoE might actually be taking place within the
cells, before the secretion of apoE to the conditioned media. To
test this, we transfected apoA-II, apoE2, apoE3, and apoE4 into
doubly expressing HEK293 cells, collected cell lysates after 24 h
incubation and measured the luminescence in cell lysates (Fig.
4C). We found that apoE2, apoE3, and apoE4 did not enhance
the luminescence within cell lysates (100.0  12.7% in apoA-II,
89.9  9.7% in apoE2, 96.4  13.9% in apoE3, 92.5  2.2% in
apoE4, no significant difference). Nevertheless they strongly in-
creased the luminescence in the conditioned media (Fig. 4A),
suggesting that apoE influences A oligomers only in the extra-
cellular compartment.
These data suggest that lipidated apoE2, 3, or 4 supports oli-
gomeric A generation to different extents, and we hypothesized
that this was due to differences in their conformation (Jones et al.,
2011). apoE2 and apoE3 prefer an open conformation, whereas
apoE4 prefers a closed conformation due to a difference at amino
acid residue 112 between apoE4 (Arg) and apoE2, E3 (Cys)
(Dong et al., 1994; Mahley et al., 2009); indirectly this changes a
salt bridge and alters the domain–domain interactions of the
amino and carboxyl halves of apoE. To test the hypothesis that
the difference of the tertiary structure of apoE is responsible for
the observed isoform-dependent differences in apoE’s facilita-
tion of oligomer formation, we examined the effects of the apoE4
R61T mutation, which is known to change the apoE4 conforma-
tion so that it mimics the closed apoE3 conformation (Ye et al.,
2005). We transiently transfected apoA-II, apoE3, apoE4, or
apoE4 R61T into doubly expressing HEK293 cells, collected con-
ditioned media after 24 h incubation, and measured its lumines-
cence in the media (Fig. 4D). We found that apoE4 R61T
increased the level of A oligomers to the same extent as apoE3,
but not as high as apoE4, suggesting that the tertiary structure of
apoE is relevant to the apoE isoform-dependent effect on A
oligomerization (100.80 7.4% in apoA-II, 228.8 15.8% with
apoE3, 260.8  17.7% with apoE4, 228.4  10.9% with apoE4
R61T; p 0.05, E4 vs E4 R61T). We did not see any difference in
the levels of apoE expression among apoE3, apoE4, and ApoE4
R61T.
We previously demonstrated that the split-luciferase-tagged
A oligomers consist of HMW 2436 mer and low-molecular
weight dimers by SEC analyses (Hashimoto et al., 2011). To eval-
uate whether apoE shifts the molecular size of A oligomers, we
separated conditionedmedia from apoE2, apoE3, or apoE4 tran-
siently transfected doubly expressing HEK293 cells using a single
Figure 4. ApoE enhanced the level of A oligomers in an isoform-dependent manner. A,
Transient transfection of GFP (control), apoA-II, apoE2, apoE3, or apoE4 into double-expressing
HEK293 cells. Luminescence of conditionedmediawasmeasured. apoE3 significantly increased
the luminescence compared with apoE2 and apoE4 significantly increased the luminescence
compared with apoE3. N	 6, average SD, *p 0.05, one-way ANOVA test (Bonferroni’s
test). B, Immunoblotting of conditioned media from GFP (control), apoE2, apoE3, or apoE4
transiently transfected double-expressing HEK293 cells by an anti-apoE mAb 3H1. C, Transient
transfection of apoA-II, apoE2, apoE3, or apoE4 into double-expressing HEK293 cells. Lumines-
cenceof cell lysateswasmeasured. There is no significantdifferenceof the luminescenceamong
apoE2-, apoE3-, or apoE4-expressing cells. N	 6, average SD, one-way ANOVA test (Bon-
ferroni’s test). D, Transient transfection of apoA-II, apoE3, apoE4, or apoE4 R61T mutant into
double-expressing HEK293 cells. Luminescence of conditioned media was measured. apoE4
significantly increased the luminescence compared with apoE4 R61T mutant. N	 6, aver-
age SD, *p 0.05, one-way ANOVA test (Bonferroni’s test). E, Transient transfection of
apoE2, apoE3, or apoE4 into double-expressing HEK293 cells and separation of conditioned
media by a SEC column Superdex 200. Representative data of the luminescence profile of the
elutants from conditioned media of apoE2 (circles)-, apoE3 (triangles)-, or apoE4 (squares)-
transfected cells. Two peaks, HMW oligomers and dimers (arrows) were observed. F, Average
ratio between HMWoligomers and dimers.N	 3, average SD, *p 0.01, one-way ANOVA
test (Bonferroni’s test).
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Superdex 200 SEC column, collected the eluted fractions, and
measured their luminescence (Fig. 4E). We found that apoE4
significantly increased the level of HMW putative 2436 mer
oligomers (or complexes of A with other proteins) and de-
creased the level of dimers (Fig. 4E,F, p 0.01). We observed no
significant shift in the elution profile of A oligomers by apoEs.
apoA-I and apoJ/clusterin also enhanced A oligomerization
In addition to apoE, apoA-I, apoA-II, and apoJ/clusterin are also
present on the HDL particles in the brain. Recently, several
genome-wide association studies have identified a variant atCLU
(gene of apoJ/clusterin) to be associated with Alzheimer’s disease
(Harold et al., 2009; Lambert et al., 2009). It has also been re-
ported that apoJ/clusterin-deficient mice crossed with APP-
transgenicmice exhibit significantly fewer fibrillar A deposits in
the brain compared with APP-transgenic mice (DeMattos et al.,
2002). Hence we asked whether these other apolipoproteins
might also modulate A oligomerization. To address this ques-
tion, we transiently transfected apoA-I, apoA-II, apoJ, and apoE3
into doubly expressing HEK293 cells, collected their conditioned
media after 24 h incubation, and measured their luminescence
(Fig. 5). Interestingly, apoA-I and apoJ/clusterin also enhanced
the luminescence, although to a lesser extent than apoE3,whereas
apoA-II did not change the luminescence from baseline (132.0
7.0% in apoA-I, 89.3 6.6% in apoA-II, 163.5 12.1% in apoJ/
clusterin, 278.8 26.0% in apoE3, p 0.05). This suggests that
apoA-I and apoJ/clusterin may also modulate the metabolism of
A oligomers in the brain, and reinforces the idea that lipidated
particles supported by several apolipoproteins may act as a scaf-
fold for A interactions.
The lipid-binding domain of apoE is necessary for
enhancement of A oligomerization
apoE has a receptor-binding domain in the N-terminal region
and a lipid-binding domain in the C-terminal region (Fig. 6A;
Chou et al., 2005). To understand which domain of apoE is im-
portant in the enhancement of A oligomerization, we expressed
the apoE NTFs (apoE2 NTF, apoE3 NTF, apoE4 NTF) or apoE
CTF in double-expressing HEK293 cells, collected conditioned
media after 24 h incubation and measured their luminescence
(Fig. 6B,C). We found that apoE2 NTF, apoE3 NTF, or apo4
NTF did not enhance the luminescence, whereas apoE CTF sig-
nificantly enhanced the luminescence to an extent similar to that
of full-length apoE3 (80.4 13.4% for apoE2NTF, 103.1 9.2%
for apoE3 NTF, 104.5  8.6% for apoE4 NTF, compared with
175.5 22.6% for apoE CTF and 191.5 13.2%with full-length
apoE3; p 0.05, apoE3 and apoE3CTF; no significant difference,
apoE2 NTF, apoE3 NTF, and apoE4 NTF). This suggests that the
C-terminal region of apoE is necessary and sufficient to induce
A oligomerization. We also coexpressed both apoE3 and apoE3
NTF together in doubly expressing HEK293 cells and found that
apoE3 NTF did not inhibit the enhancing effect of apoE3, sug-
gesting that the N-terminal fragments of apoE is a loss-of-
function molecule regarding A oligomerization (Fig. 6B,
166.9 19.2% in apoE3 and apoE3NTF, p 0.05). In immuno-
blotting, we confirmed the expression of these apoE fragments
using anti-human apoE antibodies. Mab 6C5, its epitope located
in the N-terminal region of apoE, recognized full-length apoE3,
apoE2 NTF, apoE3 NTF, and apoE4 NTF (Fig. 6A,C). Mab 3H1
(epitope located at 243–272 aa residues of apoE), recognized full-
length apoE3 and apoE CTF (Fig. 6A,C).
The C-terminal domain of apoE contains the major lipid-
binding region (243–272 aa residues; Hatters et al., 2006; Mahley et
al., 2009).To find theC-terminaldomainof apoEresponsible for the
enhancement of A oligomerization, we next expressed apoE 231–
299, apoE 243–299, apoE192–272, and apoE 192–242 in A split-
luciferase-expressing HEK293 cells, collected conditioned media
after 24h incubation, andmeasured the luminescence (Fig. 6D).We
found that apoE 231–299 and apoE 243–299 increased the lumines-
cence to the same level as apoECTF, whereas apoE 192–272 did not
increase the luminescence as strongly as apoE CTF. apoE 192–242
luminescence was even lower than that of apoE 192–272 (91.7 
3.9% in apoA-II, 274.4 24.4% in apoE3, 112.9 13.1% in apoE3
NTF, 239.0 7.6% in apoE CTF, 222.9 6.0% in apoE 231–299,
235.3  14.5% in apoE 243–299, 184.9  8.3% in apoE 192–272,
142.0 4.0% in apoE 192–242; p 0.05, apoA-II vs apoE3, apoE
CTF, apoE 231–299, or apoE 243–299; apoE CTF vs apoE 192–272;
apoE 192–272 vs apoE 192–242). Together, these data suggest that
the 243–299 aa residues in the C-terminal region of apoE are espe-
cially important in the enhancement of A oligomers. We con-
firmed similar expression levels of these apoE fragments by
immunoblotting using a goat anti-apoE polyclonal antibody and
mAb 3H1.
To further examine the effect of the 243–299 aa residues of
apoE in the enhancement of the A oligomerization, we also
expressed the deletion mutants, apoE3 243–272, apoE3 273–
299, and apoE3 243–299, collected culture media after 24 h
incubation, and measured their luminescence (Fig. 6E). We
found that apoE3243–272, apoE3273–299, and apoE3243–
299 significantly decreased the level of luminescence compared
with full-length apoE3 and that apoE3 243–299 significantly
decreased the luminescence compared with apoE3 273–299
(218.1 19.7% in apoE3, 114.0 7.1% in apoE3 NTF, 205.9
7.2% in apoE CTF, 154.4  6.8% in apoE3 243–272, 176.8 
13.5% in apoE3 273–299, 143.8  10.0% in apoE3 243–299;
p  0.01, apoA-II vs apoE3 or apoE CTF; p  0.05, apoE3 vs
apoE3 243–272, apoE3 273–299, or apoE3 243–299; apoE3
273–299 vs apoE3 243–272 or apoE3 243–299). We con-
firmed similar expression levels of these apoEmutants by immu-
noblotting usingmAb 6C5 andmAb 3H1. Together, these results
strongly argue that the C-terminal region of apoE, especially a
domain within amino-acid residues 243–272, is essential for
apoE’s support of A oligomers. This domain is the major lipid-
binding domain of apoE; thus, the lipidation of apoE may be
crucial in the enhancement of A oligomerization, as this region
may act to help catalyze oligomer formation.
Figure5. ApoA-I andapoJenhanced the level ofAoligomers. Transient transfectionofGFP
(control), apoA-I, apoA-II, apoJ/clusterin, or apoE3 into double-expressing HEK293 cells. Lumi-
nescence of conditioned media was measured. apoA-I, apoJ/clusterin, or apoE3 significantly
increased the luminescence. N	 6, average SD, *p 0.05, one-way ANOVA test (Bonfer-
roni’s test).
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Human brain apoE promoted A oligomerization
Since lipidated apoE particles generated in culture enhanced A
oligomerization, we next tested whether apoE isolated from hu-
man brain might have the same effect. We separated the TBS-
extract of human brain by SEC and fo-
und both apoE and HMW A oligomers
are eluted into fraction 7 and 8 (Fig. 2B).
We first incubated SEC-separated TBS-
soluble fractions 6–9 from AD APOE
3/3 brains, ADAPOE 4/4 brains (Fig.
7A), or control brains (Fig. 7B) with con-
ditioned media from doubly expressing
HEK293 cells for 24 h at 37°C, and mea-
sured the luminescence.We observed that
all four fractions, but especially fraction 8
from both AD and control brains, in-
creased the luminescence (141.8% in AD
fraction 6, 198.4% in AD fraction 7,
256.4% in AD fraction 8, 207.6% in AD
fraction 9, 99.8% in control fraction 6,
163.2% in control fraction 7, 230.8% in
control fraction 8, 202.6% in control frac-
tion 9). We also found that apoE eluted in
fraction 8 from AD and control brain by
immunoblotting using a goat anti-apoE
antibody (Fig. 7A,B, bottom). Next, to
test the hypothesis that apoEmediated the
increase in luminescence observed due to
fraction 8, we immunodepleted apoE
from fraction 8using an anti-human apoE
mAb 3H1, incubated with conditioned
media from doubly expressing HEK293
cells for 24 h at 37°C, and measured the
luminescence (Fig. 7C). We found that
apoE-immunodepleted sample signifi-
cantly decreased the level of luminescence
compared with immunodepletion using a
control antibody (261.8 47.3% with no
antibody, 168.1  44.6% with anti-apoE
antibody, 237.1 24.5%with control an-
tibody, p  0.05). Moreover, it is these
fractions that were used for the immuno-
precipitation of apoE and A described
above (Fig. 2C). Finally, we incubated
fraction 8 from 4 AD patients with the
APOE 4/4 genotype and 4 AD patients
with the APOE 3/3 genotype with con-
ditioned media from doubly expressing
HEK293 cells for 24 h at 37°C, and mea-
sured the luminescence (Fig. 7D). We ob-
served that fractions from APOE 4/4
AD patients led to significantly increased
levels of Aoligomers comparedwith that
from APOE 3/3 AD patients (193.0 
4.9% in APOE 4/4 AD patients and
167.6 6.8% inAPOE 3/3ADpatients,
p 0.05). These data indicate that endog-
enous apoE from human brain increased
the level of A oligomers, supporting the
hypothesis that lipidated apoE derived
from human brain also enhances A oli-
gomerization. The residual enhancement
of luminescence after immunodepletion
might be due to incomplete immunodepletion, the preservation
of lipidated particles that donot contain apoE, or other non-apoE
factors (including oligomeric A itself) that might act as a nidus
for oligomer formation.
Figure 6. Lipid-binding domain of apoE was necessary for the enhancement of A oligomers. A, Schematic structure of
apoE and apoE fragments. The epitopes of mAb 6C5 and mAb 3H1 is illustrated. B, Transient transfection of GFP, apoE3,
apoE2 NTF, apoE3 NTF, apoE4 NTF, apoE CTF, or both apoE3 and apoE3 NTF into double-expressing HEK293 cells. Lumines-
cence of conditioned media was measured. apoE3 and apoE CTF significantly increased the luminescence, on the other
hand, apoE2 NTF, apoE3 NTF, or apoE4 NTF did not increase the luminescence. N	 6, average SD, *p 0.05, one-way
ANOVA test (Bonferroni’s test). C, Immunoblotting of conditioned media by the anti-apoE mAb 6C5 (top) and 3H1 (bottom
panel). MAb 6C5 revealed 36 kDa band (full-length apoE, arrowhead) and 26 kDa band (apoE NTF, arrow). MAb 3H1
revealed also 36 kDa band (full-length apoE, arrowhead) and 10 kDa doublet band (apoE CTF, arrow). D, Transient
transfection of GFP, apoA-II, apoE3, apoE3 NTF, apoE CTF, apoE 231–299, apoE 243–299, apoE 192–272, and apoE
192–242 into double-expressing HEK293 cells. Luminescence of conditioned media was measured. apoE3 significantly
increased the luminescence comparedwith apoA-II, apoE CTF fragments. apoE CTF significantly increased the luminescence
compared with apoE 192–272 and apoE 192–272 significantly increased the luminescence compared with apoE 192–242.
N	 6, average SD, *p 0.05, one-way ANOVA test (Bonferroni’s test). E, Transient transfection of GFP, apoA-II, apoE3,
apoE3 NTF, apoE CTF, apoE3 243–272, apoE3 273–299, and apoE3 243–299 into double-expressing HEK293 cells.
Luminescence of conditioned media was measured. apoE3 and apoE CTF significantly increased the luminescence com-
pared with apoA-II. ApoE3 also significantly increased the luminescence compared with three apoE3 deletion mutants.
ApoE3273–299 significantly increased the luminescence compared with apoE3243–272 or apoE3243–299. N	 6,
average SD, *p 0.01, **p 0.05, one-way ANOVA test (Bonferroni’s test).
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Discussion
In this study, we demonstrate that the levels of A oligomers in
TBS-soluble fraction of AD APOE 4/4 brains are 2.7-fold
higher compared with APOE 3/3 patient brains and 6.9-fold
higher comparedwithAPOE 2/x patient brains, whereas brains
from non-demented controls had negligible levels of A oligom-
ers (Fig. 1A,B). We also found that A and apoE coeluted into
HMW fractions in SEC-separated TBS-soluble fraction from AD
brains, and coimmunoprecipitated (Fig. 2B,C), suggesting the
possibility of an in vivo interaction between them.We confirmed
thatA and apoE coeluted intoHMWfractions in SEC-separated
interstitial fluid fromAPP-PSmouse brains using amicrodialysis
techniques with a 1000 kDa molecular weight cutoff membrane
probe (S. Takeda, T. Hashimoto, and B. T. Hyman, unpublished
observation), suggesting that the apoE and A HMW complex
endogenously exists in the brain and is not a product caused
during the mechanical homogenization steps.
Based on these data, we hypothesized that apoE would facili-
tate A oligomerization, and tested the idea that the extent of
oligomer formationwould be isoformdependent.We performed
A oligomerization assays using three different preparations of
apoE. First, apoE on HDL particles, purified from conditioned
media of immortalized astrocytes expressinghumanapoE2,apoE3,
or apoE4, promoted the oligomerization of synthetic A, split-
luciferase-taggedAoligomers,orLMWA isolatedfromTBS-soluble
fraction of AD patients’ brains A (Fig. 3). Second, transient overex-
pression of apoE2, apoE3, or apoE4 in HEK293 cells stably express-
ing split-luciferase-tagged A oligomers increased A oligomers
through apoE’s C-terminal domain in an isoform-dependent man-
ner (apoE2 apoE3 apoE4; Figs. 4, 6). Third, endogenous apoE
extracted from TBS-soluble fraction of human AD and control
brains also increased A oligomers, again apoE3 apoE4 (Fig. 7).
Similarly, we assessed oligomerization using two preparations: syn-
theticA and aquantitative split-luciferase assay,with confirmatory
results. apoE, especially apoE4, appears to enhance A oligomers.
The current view of AD pathophysiology emphasizes the del-
eterious effects of A oligomers on synapses, leading to synaptic
dysfunction, and progressive memory impairment in AD pa-
tients (Lesne´ et al., 2006; Shankar et al., 2008; Li et al., 2009;Wu et
al., 2010). Recently we found that apoE colocalized with A oli-
gomers at synapse in the brain of ADpatient brains using an array
tomographic technique and found that APOE 4/4 AD patients
have a significantly higher level of colocalization of apoE and A
oligomers at synapse compared with APOE 3/3 AD patients
(Koffie et al., 2012). Our results suggest that apoE4 increases the
level of A oligomers in the brain, leading to increased synaptic
localization with A oligomers, synaptic dysfunction, and has-
tening the development of cognitive impairments.
Biochemical analyses of human AD revealed that the level of
TBS-soluble A oligomers in APOE 4/4 brains are 2.7-fold
higher compared with AD APOE 3/3 brains and 6.9-fold
higher compared with AD APOE 2/x brains (Fig. 1A,B). Im-
portantly, these AD groups were matched for deposited amyloid
burden. No significant correlation was observed between plaque
burden and levels of TBS-soluble A oligomers (r	
0.01, p	
0.95, Spearman’s rank correlation test), so that the 2.7-fold dif-
ference in the levels of TBS-soluble A oligomers between them
cannot be attributed to the disruption of a higher amount of
senile plaques in the APOE 4/4 group during the homogeniza-
tion of the specimens. Thus, these results indicate that apoE in-
fluences both plaque burden and also the levels of TBS-soluble
A oligomers in an isoform-differential manner.
Using both synthetic A (Fig. 3A) and a split-luciferase com-
plementation assay (Figs. 3C, 4), we found that apoE increased
A oligomerization in an isoform-dependent manner (apoE2
apoE3  apoE4). Interestingly, experiments using deletion mu-
tants of apoE demonstrate that the C-terminal domain of apoE is
necessary and sufficient to drive A oligomerization, suggesting
that apoE may directly interact with A oligomers through its
C-terminal region (Fig. 6B,D,E). We also found that apoE4 en-
hanced the ratio ofHMWA oligomers comparedwith apoE2 or
apoE3 (Fig. 4E,F), suggesting that N-terminal domain might be
important to modulate A oligomerization. In a recent study
using the anti-apoEmAb 3H1, which recognizes the amino acids
243–272, we observed significantly higher levels of apoE
C-terminal fragments in APOE 4/4 AD brains compared with
APOE 3/3 AD brains. In addition, using in situ fluorescence
lifetime imaging–fluorescent resonance energy transfer in hu-
man AD brain specimens, we found that A is closer to the apoE
C-terminal region than to its N-terminal region within doubly
labeled senile plaques (Jones et al., 2011). Together, these results
argue that not only full-length apoE4 but also C-terminal frag-
ments of apoE4 containing the region at 243–272 amino-acid
residues may additionally enhance the formation of A oligom-
ers in APOE 4/4 brains. Interestingly, the 243–272 aa residues
of apoE are the major lipid-binding region of apoE, supporting
Figure 7. Endogenous apoE in the brain increases the level of A oligomers. A,B, Lumines-
cence of SEC-separated fraction 6, 7, 8, or 9 from TBS-soluble fraction of AD (A) or control (B)
brain incubated with split-luciferase-tagged A oligomers for 24 h. An anti-apoE antibody
revealed 36 kDa apoE protein (bottom). C, Immunodepletion of fraction 8 of AD brains using no
antibody, anti-apoE mAb 3H1 or control Ig. Luminescence from immunodepleted fraction 8 of
AD brains incubated with split-luciferase-tagged A oligomers for 24 h. Anti-apoE mAb 3H1
significantly reduced the luminescence comparedwith control Ig. N	 4, average SD, *p
0.05, one-way ANOVA test (Bonferroni’s test). D, Luminescence of SEC-separated fraction 8
from TBS-soluble fraction of 4 APOE 4/4 AD brains and 4 APOE 3/3 AD brains incubated
with split-luciferase-tagged A oligomers for 24 h. Fraction 8 from APOE 4/4 AD brains
significantly increased the level of A oligomers compared with that APOE 3/3 AD brains.
Average SD, *p 0.05, one-way ANOVA test (Bonferroni’s test).
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the idea that apoE lipidation may be critical to facilitate A oli-
gomer formation. We hypothesize that lipidated apoE might
concentrate A monomer and provide a scaffold for oligomer-
ization of A. Alternatively, we found lipidated apoE4 increased
the level of synthetic A trimers and tetramers (Fig. 3B), suggest-
ing that lipidated apoE, especially apoE4, might stabilize A oli-
gomers and inhibit the dissociation or further aggregation of A.
Furthermore, A oligomers may be able to escape from A deg-
radation or phagocytosis by binding to apoE on HDL particles.
In addition to apoE, we found apoJ/clusterin and apoA-I,
other apolipoproteins on theHDLparticles, increased the level of
A oligomers (Fig. 5). Common variants in the apoJ/clusterin
gene (CLU) have recently been linked to an increased risk of
developing AD (Harold et al., 2009; Lambert et al., 2009), and
apoJ/clusterin-deficient mice crossed with APP-transgenic mice
exhibit significantly fewer fibrillar A deposits in the brain com-
paredwith APP-transgenicmice (DeMattos et al., 2002), suggest-
ing that apoJ/clusterinmaymodify A oligomer formation in the
human brain similarly to apoE. By contrast, crossing apoA-I-
deficient mice with APP-transgenic mice did not alter A depo-
sition in the brain (Fagan et al., 2004), indicating a small or no
effect of apoA-I on A oligomerization and fibrillization. We
observed that apoA-I only slightly increased the levels of A oli-
gomers (Fig. 5).
Recently, it was reported that the level of soluble oligomeric
A in frontal cortex of young adults is higher than that of
elderly people or Alzheimer’ disease patients using ELISA ex-
periments (van Helmond et al., 2010), potentially calling into
question a relationship between oligomeric A (as measured
by the ELISA) with Alzheimer disease pathogenesis. In this
study we observed that the level of HMW A from TBS-
soluble fraction is under-estimated in ELISA experiments due
to a possible masking effect either by itself or interacting mol-
ecules, and the treatment with 8 M Guanidine-HCl increases
the measured concentration of A in HMW A fractions us-
ing our specific ELISA conditions (Fig. 2A). It would be inter-
esting to evaluate the age-dependent ELISA results in the
context of these technical issues of A measurement.
In summary, we provide in vivo and in vitro evidence that
apoE interacts with A oligomers through its C-terminal region
and that apoE, particularly apoE4, promotes and stabilizes A
oligomerization. Given the relatively large magnitude of these
effects (e.g., a 2.7-fold increase in A oligomers in APOE 4/4
Alzheimer brains, compared with APOE E3/3 Alzheimer brains),
it is plausible that these observations help explain the major risk
for AD associated with APOE 4 inheritance. Both the inhibition
of the interaction between apoE and A oligomers and the inhi-
bition of the lipidation of apoE may be valuable therapeutic tar-
gets to prevent A oligomerization and subsequent synaptic
dysfunction.
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